ISSN: 2148-4902 | E-ISSN: 2536-4553
Northern Clinics of Istanbul Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis [North Clin Istanb]
North Clin Istanb. 2018; 5(1): 64-66 | DOI: 10.14744/nci.2017.77045

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis

Fazia A. Mir, Alhareth Al Juboori, Jack D. Bragg, Veysel Tahan
Department of Gastroenterology and Hepatology, Missouri University, Columbia, Missouri, USA

Infliximab is a monoclonal antibody that antagonizes the activity of tumor necrosis factor alpha to induce and maintain remission in patients with inflammatory bowel disease. Adverse effects associated with Infliximab infusions include infusion reactions, risk of infections, development of hematological malignancies, and pancytopenia. Autoimmune hemolytic anemia has rarely been reported in ulcerative colitis. Herein we report a case of drug-induced hemolytic anemia after infliximab infusion for treating ulcerative colitis.

Keywords: Autoimmune hemolytic anemia, inflammatory bowel disease; infliximab; ulcerative colitis.

Fazia A. Mir, Alhareth Al Juboori, Jack D. Bragg, Veysel Tahan. Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis. North Clin Istanb. 2018; 5(1): 64-66

Corresponding Author: Veysel Tahan, United States
Manuscript Language: English
LookUs & Online Makale